drugset / Trial / NCT06828120

A Randomized, Safety and Efficacy Study of Taneasy 600mg Granules and Fluimucil 600mg Granules in COPD Subjects

NCT06828120

RandomizedParallel-groupOpen-labelTreatment

Summary

To evaluate the safety and efficacy of Taneasy 600mg granules and Fluimucil 600mg granules administered twice daily for 14 days in treatment of COPD Disease.

Timeline

Start
2025-02-20
Primary completion
2025-09-03
Completion
2025-09-17

Drugs

EvaluationDrugModalityDoseRoute
Subject N-acetylcysteine Small molecule 600 mg
Subject Taneasy Unknown 600 mg